In Brief This Week: Abbott; PerkinElmer; Medical College of Wisconsin; Leica Biosystems; Accelrys; Five3 Genomics | GenomeWeb

NEW YORK (GenomeWeb News) – Abbott said this week that it will expand the current CE-IVD product labeling for its Vysis ALK Break Apart FISH Probe Kit, allowing the test to be marketed in the European Union as a companion diagnostic. The test is designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in advanced non-small cell lung cancer patients who may be eligible for treatment with Pfizer's Xalkori (crizotinib), an oral first-in-class ALK inhibitor.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.